Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 2/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.41 |
| ▸ | ELANE | P08246 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.39 |
| ▸ | FPR2 | P25090 | 6/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4078297 | 0.83 | MAT2A (0.47) | MAT2AACVR1ELANETSHRSCN9A | |
| SCHEMBL4084126 | 0.83 | MAT2A (0.47) | MAT2AACVR1ELANETSHRSCN9A | |
| SCHEMBL4083507 | 0.82 | MAT2A (0.43) | MAT2AACVR1ELANETSHRSCN9A | |
| SCHEMBL7751006 | 0.82 | MAT2A (0.46) | MAT2AACVR1ELANETSHRSCN9A | |
| SCHEMBL4077720 | 0.81 | MAT2A (0.47) | MAT2AACVR1ELANETSHRSCN9A | |
| SCHEMBL7749780 | 0.81 | MAT2A (0.47) | MAT2AACVR1ELANETSHRSCN9A | |
| SCHEMBL7751002 | 0.80 | MAT2A (0.43) | MAT2AACVR1ELANETSHRSCN9A | |
| SCHEMBL7749860 | 0.79 | ACVR1 (0.43) | MAT2AACVR1ELANETSHRSCN9A | |
| SCHEMBL4078860 | 0.79 | ACVR1 (0.43) | MAT2AACVR1ELANETSHRSCN9A | |
| SCHEMBL5675162 | 0.78 | MAT2A (0.44) | MAT2AELANETSHRSCN9AFPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598252-B2 | Compounds specific to adenosine A, receptors and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080070936-A1 | Compounds specific to adenosine A1 receptors and uses thereof | OSI PHARMACEUTICALS, INC. | 2008-03-20 | — | — | US | disclosed |
| EP-1731520-A1 | Pyrrolo[2,3-d]pyrimidine derivatives which are antagonists of adenosine A1, A2A, and A3 | OSI Pharmaceuticals, Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| US-20040082599-A1 | Compounds specific to adenosine A1 receptors and uses thereof | OSI PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040082598-A1 | Compounds specific to adenosine A, receptors and uses thereof | OSI PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-6680322-B2 | FOR THERAPY OF ASTHMA, ALLERGIC RHINITIS, RESPIRATORY SYSTEM DISORDERS | OSI PHARMACEUTICALS, INC. | 2004-01-20 | — | — | US | disclosed |
| US-6680324-B2 | 4-AMINO-6-PHENYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2004-01-20 | — | — | US | disclosed |
| EP-1246623-A4 | COMPOUNDS SPECIFIC TO ADENOSINE A1, A2A, AND A3 RECEPTOR AND USES THEREOF | OSI PHARM INC (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20030045536-A1 | Compounds specific to adenosine A1 receptors and uses thereof | OSI PHARMACEUTICALS, INC. | 2003-03-06 | — | — | US | disclosed |
| EP-1246623-A1 | COMPOUNDS SPECIFIC TO ADENOSINE A1, A2A, AND A3 RECEPTOR AND USES THEREOF | OSI Pharmaceuticals, Inc. (US) | 2002-10-09 | — | — | EP | disclosed |
| US-20020058667-A1 | Compounds specific to adenosine A1 receptors and uses thereof | OSI PHARMACEUTICALS, INC. | 2002-05-16 | — | — | US | disclosed |
| WO-2001039777-A1 | COMPOUNDS SPECIFIC TO ADENOSINE A1 A2A, AND A3 RECEPTORS AND USES THEREOF | OSI PHARMACEUTICALS, INC. (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082598-A1 | Compounds specific to adenosine A, receptors and uses thereof | ADORA2A, ADORA1, ADORA3 | MAT2A 305/4885ACVR1 462/4885ELANE 1937/4885 |
| US-20020058667-A1 | Compounds specific to adenosine A1 receptors and uses thereof | ADORA1, ADORA2A, ADORA3 | MAT2A 324/4885ACVR1 471/4885ELANE 1603/4885 |
| US-20030045536-A1 | Compounds specific to adenosine A1 receptors and uses thereof | ADORA1, ADORA2A, ADORA3 | MAT2A 324/4885ACVR1 471/4885ELANE 1603/4885 |
| US-20080070936-A1 | Compounds specific to adenosine A1 receptors and uses thereof | ADORA1, ADORA2A, ADORA3 | MAT2A 285/4885ACVR1 470/4885ELANE 1552/4885 |
| US-20040082599-A1 | Compounds specific to adenosine A1 receptors and uses thereof | ADORA1, ADORA2A, ADORA3 | MAT2A 324/4885ACVR1 471/4885ELANE 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.